DIROXIMEL FUMARATE

/static/temp/default.svg

Search structure


Synonyms	ALKS 8700 ALKS-8700 ALKS8700 Alks 8700 BIIB-098 BIIB098 Diroximel fumarate RDC-5108 RDC5108 Vumerity
Status
Molecule Category	UNKNOWN
UNII	K0N0Z40J3W


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YIMYDTCOUQIDMT-SNAWJCMRSA-N
Smiles	COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O
InChI	InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C11H13NO6
Molecular Weight	255.23
AlogP	-0.59
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	5.0
Polar Surface Area	89.98
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	18.0

Bioactivity

Mechanism of Action	Action	Reference
Kelch-like ECH-associated protein 1 inhibitor	INHIBITOR	FDA PubMed PubMed

Assay Description	Organism	Bioactivity	Reference
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	5.18 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	7.103 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.44 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.44 %

Cross References

Resources	Reference
ChEMBL	CHEMBL3989944
DrugBank	DB14783
FDA SRS	K0N0Z40J3W
Guide to Pharmacology	10525
PubChem	73330464
SureChEMBL	SCHEMBL15499960
ZINC	ZINC000215286156

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).